March 30, 2023

Jan Skvarka isn’t a household name in biotech. Maybe he should be. Skvarka was previously the CEO of Trillium Therapeutics, where he led a remarkable turnaround of the Canadian small cap biotech into a leading immune oncology player. Trillium had a market capitalization of $16 million when he started. Over the next two years, he led it to a $2.26... Read More